Pfizer Taps IBM For Research Collaboration To Transform Parkinson’s Disease

Pfizer Taps IBM For Research Collaboration To Transform Parkinson’s Disease
April 13 10:14 2016 Print This Article

(Pharmiweb) – Pfizer Inc. (NYSE:PFE) and IBM (NYSE:IBM) has announced a first-of-its-kind research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease.

The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The ultimate goal is to obtain a better understanding of a patient’s disease progression and medication response to help inform treatment decisions and clinical trial design, while also speeding the development of new therapeutic options.

Parkinson’s disease in particular requires ongoing adjustment to medication depending on the progression of the disease and response of the patient. The collaboration seeks to create a holistic view of a patient’s well-being by seeking to accurately measure a variety of health indicators, including motor function, dyskinesia, cognition, sleep and daily activities such as grooming, dressing and eating. Insights from these data could help clinicians understand the effect of a patient’s medication as the disease progresses, enabling them to help optimize the patient’s treatment regimen as needed. Data generated through the system could also arm researchers with the insights and real-world evidence needed to help accelerate potential new and better therapies.

See the full article HERE

  Article "tagged" as:
  Categories: